Chimerix (NASDAQ:CMRX) Now Covered by StockNews.com

StockNews.com began coverage on shares of Chimerix (NASDAQ:CMRX) in a report published on Thursday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

A number of other equities research analysts have also recently weighed in on CMRX. HC Wainwright restated a “neutral” rating and issued a $8.55 price target (down previously from $11.00) on shares of Chimerix in a report on Wednesday, March 5th. Wedbush reissued a “neutral” rating and issued a $8.55 target price (up previously from $7.00) on shares of Chimerix in a research note on Wednesday, March 5th. Finally, Jefferies Financial Group reissued a “hold” rating and issued a $8.50 price objective (down previously from $10.00) on shares of Chimerix in a research report on Wednesday, March 5th.

Chimerix Stock Performance

Shares of Chimerix stock opened at $8.54 on Thursday. The business’s 50 day moving average price is $7.79 and its 200 day moving average price is $4.26. The company has a market cap of $801.09 million, a price-to-earnings ratio of -9.09 and a beta of -0.17. Chimerix has a one year low of $0.75 and a one year high of $8.55.

Chimerix (NASDAQ:CMRX) last posted its quarterly earnings data on Friday, March 21st. The biopharmaceutical company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.01. The business had revenue of $0.06 million during the quarter, compared to analysts’ expectations of $0.31 million. On average, analysts predict that Chimerix will post -0.99 EPS for the current fiscal year.

Insider Buying and Selling

In other Chimerix news, CEO Michael T. Andriole sold 7,370 shares of Chimerix stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $4.52, for a total transaction of $33,312.40. Following the completion of the transaction, the chief executive officer now directly owns 609,603 shares of the company’s stock, valued at approximately $2,755,405.56. This trade represents a 1.19 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 20,760 shares of company stock worth $91,175 in the last quarter. 13.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Chimerix

Institutional investors have recently modified their holdings of the business. Assenagon Asset Management S.A. raised its stake in Chimerix by 154.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 817,739 shares of the biopharmaceutical company’s stock worth $2,846,000 after buying an additional 496,823 shares during the period. Stoneridge Investment Partners LLC raised its holdings in shares of Chimerix by 22.5% during the fourth quarter. Stoneridge Investment Partners LLC now owns 44,305 shares of the biopharmaceutical company’s stock worth $154,000 after acquiring an additional 8,134 shares during the period. Peapod Lane Capital LLC bought a new stake in Chimerix in the 4th quarter valued at $2,626,000. Valeo Financial Advisors LLC boosted its stake in Chimerix by 78.8% in the 4th quarter. Valeo Financial Advisors LLC now owns 146,186 shares of the biopharmaceutical company’s stock worth $509,000 after purchasing an additional 64,420 shares during the period. Finally, Palumbo Wealth Management LLC bought a new position in Chimerix during the 4th quarter worth about $221,000. Institutional investors and hedge funds own 45.42% of the company’s stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.